SAB Biotherapeutics's market cap is currently $18.00M. The company's EPS TTM is $-6.31; its P/E ratio is ―; SAB Biotherapeutics is scheduled to report earnings on May 8, 2025, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 2.24M	$ 23.90M	$ 60.88M	$ 55.24M	$ 3.44M
Gross Profit	$ -1.51M	$ 20.61M	$ 59.22M	$ 55.24M	$ 3.44M
Operating Income	$ -38.08M	$ -28.92M	$ -13.39M	$ 20.56M	$ -8.67M
EBITDA	$ -38.13M	$ -15.12M	$ -15.20M	$ 21.14M	$ -8.23M
Net Income	$ -42.19M	$ -18.74M	$ -17.44M	$ 20.12M	$ -9.42M
Balance Sheet
Cash & Short-Term Investments	$ 56.57M	$ 15.05M	$ 33.21M	$ 12.61M	$ 6.35M
Total Assets	$ 83.94M	$ 50.90M	$ 79.37M	$ 56.54M	$ 18.00M
Total Debt	$ 5.91M	$ 5.93M	$ 6.74M	$ 8.13M	$ 7.64M
Net Debt	$ -50.66M	$ -9.12M	$ -26.46M	$ -4.48M	$ 1.29M
Total Liabilities	$ 26.64M	$ 19.85M	$ 40.82M	$ 17.53M	$ 20.31M
Stockholders' Equity	$ 57.30M	$ 31.06M	$ 38.55M	$ 39.01M	$ -2.31M
Cash Flow
Free Cash Flow	$ -25.32M	$ -7.19M	$ -7.19M	$ -2.73M	$ -9.82M
Operating Cash Flow	$ -25.12M	$ 3.76M	$ 3.76M	$ 10.00M	$ -9.21M
Investing Cash Flow	$ -152.70K	$ -10.94M	$ -10.94M	$ -12.72M	$ -608.75K
Financing Cash Flow	$ 66.77M	$ 34.12M	$ 34.12M	$ 8.98M	$ 3.68M

Currency in USD

SAB Biotherapeutics Earnings and Revenue History

Income Statement >

SAB Biotherapeutics Debt to Assets

Balance Sheet >

SAB Biotherapeutics Cash Flow

Cash Flow >

SAB Biotherapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing